Abbott Laboratories (NYSE:ABT) is in the midst of some dramatic new plans. The company will soon spin off its branded pharmaceuticals business into a new entity called AbbVie. The original Abbott Laboratories will still maintain a solid mix of health care businesses. But the new spinoff has many more dynamic questions around it, since it will be heavily reliant on Abbott's powerhouse autoimmune drug, Humira, which is quickly becoming the world's best seller. In this video, Motley Fool health care analyst Brenton Flynn outlines AbbVie's situation in more detail and points out one area that could hold the key to AbbVie's future after Humira loses patent protection.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.